Publications since 2010

Heber N, Kuhn BJ, Strobel TD, Lohrey C, Krijgsveld J, Hoppe-Seyler K, Hoppe-Seyler F (2023)
The Impact of Cycling Hypoxia on the Phenotype of HPV-Positive Cervical Cancer Cells.
J. Med. Virol., 95: e29280

 Strobel TD, Weber M, Heber N, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F (2023)
Revisiting the Role of Endogenous STAT3 in HPV-Positive Cervical Cancer Cells.
J. Med. Virol., 95: e29230

Vučković N, Hoppe-Seyler K, Riemer AB (2023)
Characterization of DoTc2 4510-Identifying HPV16 Presence in a Cervical Carcinoma Cell Line Previously Considered to Be HPV-Negative.
Cancers, 15: 3810.

Schifflers C, Zottnick S, Förster JD, Kruse S, Yang R, Wiethoff H, Bozza M, Hoppe-Seyler K, Heikenwälder M, Harbottle RP, Michiels C, Riemer AB (2023)
Development of an orthotopic HPV16-dependent base of tongue tumor model in MHC-humanized mice.
Pathogens 12: 188.

Yang, D, Strobel TD, Bulkescher J, Tessmer C,  Hofmann I, Hoppe-Seyler F; Hoppe-Seyler K (2022)
FAM57A (Family with Sequence Similarity 57 Member A) Is a Cell-Density-Regulated Protein and Promotes the Proliferation and Migration of Cervical Cancer Cells.
Cells 11: 3309

Frensemeier K, Holzer A, Hoppe-Seyler, K, Hoppe-Seyler F (2022).
Dickkopf-1 (Dkk1) expression is repressed by oncogenic HPVs and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner.
Int. J. Cancer, 151: 2215-2228.

Herrmann AL, Kuhn BJ, Holzer A, Krijgsveld J, Hoppe-Seyler K, Hoppe-Seyler F (2021).
Delineating the switch between senescence and apoptosis in cervical cancer cells under ciclopirox treatment.
Cancers, 13: 4995.

Daum, AK, Dittmann J, Jansen L, Peters S, Dahmen U, Heger JI, Hoppe-Seyler F, Gille A, Clement JH, Runnebaum IB, Dürst M, Backsch C (2021).
ITIH5 shows tumor suppressive properties in cervical cancer cells grown as multicellular tumor spheroids.
Am. J. Transl. Res., 13, 10298-10314.

Hoppe-Seyler K, Herrmann AL, Däschle A, Kuhn BJ, Strobel T, Lohrey C, Bulkescher J, Krijgsveld J, Hoppe-Seyler F (2021).
Effects of Metformin on the virus/host cell crosstalk in HPV-positive cancer cells.
Int. J. Cancer, 149: 1137-1149.

Braun JA, Herrmann AL, Blase JI, Frensemeier K, Bulkescher J, Scheffner M, Galy B, Hoppe-Seyler K, Hoppe-Seyler F (2020).
Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis.
Int. J. Cancer, 146: 461-474.

Bossler F, Kuhn BF, Günther T, Kraemer SJ, Khalkar P, Adrian S, Lohrey C, Holzer A, Shimobayashi M, Dürst M, Mayer A, Rösl F, Grundhoff A, Krijgsveld J, Hoppe-Seyler K, Hoppe-Seyler F (2019).
Repression of Human Papillomavirus Oncogene Expression under Hypoxia is Mediated by PI3K/mTORC2/AKT Signaling.
mBIO, 10: e02323-18.

Bossler F, Hoppe-Seyler K, Hoppe-Seyler F. (2019)
PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.
Int. J. Mol. Sci. 20: pii: E2188.

Lien YH, Mahato, DR, Hoppe-Seyler F, Fischer WB (2019)
Membrane partitioning of peptide aggregates - coarse grained molecular dynamics simulations.
J. Biomol. Struct. Dyn., Feb 27: 1-9.

Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. (2018).
The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets.
Trends in Microbiology, 26: 158-168.

Honegger A, Schilling D, Sültmann H, Hoppe-Seyler K, Hoppe-Seyler F. (2018).
Identification of E6/E7-dependent microRNAs in HPV-positive cancer cells.
Methods in Molecular Biology, 1699: 119-134.

Hoppe-Seyler K, Honegger, A., Bossler F, Sponagel J, Bulkescher J, Lohrey C, Hoppe-Seyler F. (2017).
Viral E6/E7 Oncogene and Cellular Hexokinase 2 Expression in HPV-Positive Cancer Cell Lines.
Oncotarget 8, 106342-106332

Hoppe-Seyler K, Mändl J, Adrian S, Kuhn BJ, Hoppe-Seyler F. (2017).
Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells.
Viruses 9:pii: E174.

Hoppe-Seyler K, Bossler B, Lohrey C, Bulkescher J, Rösl F , Jansen L, Mayer A, Vaupel P, Dürst M, Hoppe-Seyler F. (2017).
Induction of dormancy in hypoxic human papillomavirus-positive cancer cells.
Proc. Natl. Acad. Sci. U. S. A. 114:E990-E998.

Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F. (2015).
Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells.
PLoS Pathog 11:e1004712.

Stutz C, Reinz E, Honegger A, Bulkescher J, Schweizer J, Zanier K, Travé G, Lohrey C, Hoppe-Seyler K, Hoppe-Seyler F. (2015).
Intracellular analysis of the interaction between the human papillomavirus type 16 E6 oncoprotein and inhibitory peptides.
PLoS ONE 10:e0132339.

Leitz J, Reuschenbach M, Lohrey C, Honegger A, Accardi R, Tommasino M, Llano M, von Knebel Doeberitz M, Hoppe-Seyler K, Hoppe-Seyler F. (2014).
Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene.
PLoS Pathog 10:e1003957.

Zanier K, Stutz C, Kintscher S, Reinz E, Sehr P, Bulkescher J, Hoppe-Seyler K, Travé G, Hoppe-Seyler F. (2014).
The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
PLoS ONE 9:e112514.

Honegger A, Leitz J, Bulkescher J, Hoppe-Seyler K, Hoppe-Seyler F. (2013).
Silencing of human papillomavirus (HPV) E6/E7 oncogene expression affects both the contents and the amounts of extracellular microvesicles released from HPV-positive cancer cells.
Int J Cancer 133:1631-42.

Wagener N, Bulkescher J, Macher-Goeppinger S, Karapanagiotou-Schenkel I, Hatiboglu G, Abdel-Rahim M, Abol-Enein H, Ghoneim MA, Bastian PJ, Müller SC, Haferkamp A, Hohenfellner M, Hoppe-Seyler F, Hoppe-Seyler K. (2013).
Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients.
Br J Cancer 108:973-82.

Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F. (2012).
The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro.
Hepatology 56: 9-16.

Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler, F. (2011).
EZH2 depletion blocks the proliferation of colon cancer cells.
PLoS ONE 6:e21651

Laurenson S, Pett MR, Hoppe-Seyler K, Denk C, Hoppe-Seyler F, Coleman N, Ko Ferrigno P. (2011).
Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts.
Anal Biochem 410:161-70

Hoppe-Seyler F, Hoppe-Seyler K. (2011).
Emerging topics in human tumor virology.
Int J Cancer 129:1289-99.

Crnkovic-Mertens I, Bulkescher J, Mensger N, Hoppe-Seyler F, Hoppe-Seyler K. (2010).
Isolation of peptides blocking the function of the anti-apoptotic Livin protein.
Cell Mol Life Sci 11:1895-905.

Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, Hasskarl J, Burwinkel B. (2010).
Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells.
Breast Cancer Res Treat 124:623-33.

Moosmeier MA, Bulkescher J, Hoppe-Seyler K, Hoppe-Seyler F. (2010).
Binding proteins internalized by PTD-fused ligands allow the intracellular sequestration of selected targets by ligand exchange.
Int. J Mol Med 25:557-64.

Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M. (2010).
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
BMC Cancer 10:524.

Moosmeier MA, Bulkescher J, Reed J, Schnölzer M, Heid H, Hoppe-Seyler K, Hoppe-Seyler F. (2010).
Transtactin: a universal transmembrane delivery system for Strep-tag II-fused cargos.
J Cell Mol Med 14:1935-45.


Full list of publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=hoppe-seyler-f)